PHOX2A: A Gene Regulator and Potential Drug Target (G401)

Target Name: PHOX2A

NCBI ID: G401

PHOX2A

PHOX2A: A Gene Regulator and Potential Drug Target

PHOX2A, also known as paired-like homeobox 2A, is a gene that encodes a protein located in the nucleus of the DNA. It is a key regulator of gene expression and has been implicated in the development and progression of various diseases, including cancer. As a result, it has become a focus of intense research and may be a drug target or biomarker.

PHOX2A was first identified in the early 1990s by researchers at the University of California, Berkeley. They found that the gene was highly expressed in a variety of tissues, including brain, heart, and gastrointestinal tract, and that it was involved in the development of cancer. Since then, numerous studies have confirmed its role in the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of PHOX2A is its role in cell signaling. It is a member of the homeobox gene family, which is characterized by a conserved sequence that includes a DNA-binding domain and a transmembrane region. The homeobox genes are involved in the regulation of gene expression and have been implicated in the development and progression of various diseases.

PHOX2A is involved in the regulation of a wide range of gene expression, including the expression of genes involved in cell adhesion, migration, and survival. It has been shown to play a role in the development of various cancers, including breast, ovarian, and Prostate cancers. It has also been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in disease, PHOX2A is also a potential drug target. Researchers have identified several potential small molecules that can inhibit the activity of PHOX2A, including compounds that target the protein itself or its activity modulators. These compounds have been shown to have a variety of therapeutic effects, including the inhibition of cancer growth and the improvement of neurodegenerative symptoms.

The PHOX2A gene has also been the subject of intense research as a potential biomarker. Researchers have developed techniques to measure the expression of PHOX2A in various tissues and have used these measurements to diagnose and monitor the effectiveness of cancer therapies. For example, studies have shown that the expression of PHOX2A is significantly reduced in tumors compared to normal tissue, which suggests that it may be an effective biomarker for cancer diagnosis and monitoring.

Overall, PHOX2A is a gene that has significant implications for our understanding of disease and the development of cancer. Its role in cell signaling and its potential as a drug target make it an attractive target for further research and development. As research continues to advance, the potential of PHOX2A as a biomarker and drug target will be further validated and its role in the understanding and treatment of various diseases will continue to be explored.

Protein Name: Paired Like Homeobox 2A

Functions: May be involved in regulating the specificity of expression of the catecholamine biosynthetic genes. Acts as a transcription activator/factor. Could maintain the noradrenergic phenotype

The "PHOX2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHOX2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets